FUS/TLS is a co-activator of androgen receptor in prostate cancer cells

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Haile, Simon ^a   Lal, Aaron ^a   Myung, Jae Kyung ^a   Sadar, Marianne D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BINDING PROTEIN; FUSED IN SARCOMA PROTEIN; TRANSCRIPTION FACTOR GAL4; TRANSLOCATED IN LIPOSARCOMA PROTEIN; UNCLASSIFIED DRUG; ANDROGEN; AR PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; RNA BINDING PROTEIN; TRANSACTIVATOR PROTEIN;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENHANCER REGION; GENE OVEREXPRESSION; HORMONE RESPONSE; HUMAN; HUMAN CELL; MALE; NONHUMAN; ONCOGENE; PROMOTER REGION; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PSA GENE; TRANSACTIVATION; TRANSCRIPTION INITIATION; AMINO ACID SEQUENCE; CELL FRACTIONATION; CHEMISTRY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; MASS SPECTROMETRY; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PROSTATE TUMOR; PROTEIN TRANSPORT; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANDROGENS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; MULTIPROTEIN COMPLEXES; PROSTATIC NEOPLASMS; PROTEIN TRANSPORT; RECEPTORS, ANDROGEN; RNA-BINDING PROTEIN FUS; SUBCELLULAR FRACTIONS; TRANS-ACTIVATORS; TRANSCRIPTIONAL ACTIVATION;

EID: 80052366065     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024197     Document Type: Article

References (29)

1. Wang G, Sadar MD, (2006) Amino-terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer. J Cell Biochem 98: 36-53.
2. Molina A, Belldegrun A, (2011) Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. J Urol 185: 787-794.
3. Sadar MD, (2011) Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity. Cancer Res 71: 1208-1213.
4. Law WJ, Cann KL, Hicks GG, (2006) TLS, EWS and TAF15: a model for transcriptional integration of gene expression. Brief Funct Genomic Proteomic 5: 8-14.
5. Tan AY, Manley JL, (2009) The TET family of proteins: functions and roles in disease. J Mol Cell Biol 1: 82-92.
6. Perani M, Antonson P, Hamoudi R, Ingram CJ, Cooper CS, et al. (2005) The proto-oncoprotein SYT interacts with SYT-interacting protein/co-activator activator (SIP/CoAA), a human nuclear receptor co-activator with similarity to EWS and TLS/FUS family of proteins. J Biol Chem 280: 42863-42876.
7. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, et al. (1980) The LNCaP cell line-a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 37: 115-132.
8. Wolters DA, Washburn MP, Yates JR 3rd, (2001) An automated multidimensional protein identification technology for shotgun proteomics. Anal Chem 73: 5683-5690.
9. de Hoog CL, Foster LJ, Mann M, (2004) RNA and RNA binding proteins participate in early stages of cell spreading through spreading initiation centers. Cell 117: 649-662.
10. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, et al. (1996) Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem 271: 7043-7051.
11. Cleutjens KB, van Eekelen CC, van der Korput HA, Brinkmann AO, Trapman J, (1996) Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 271: 6379-6388.
12. Sadar MD, (1999) Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem 274: 7777-7783.
13. Wang G, Jones SJ, Marra MA, Sadar MD, (2006) Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells. Oncogene.
14. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39.
15. Heemers HV, Schmidt LJ, Kidd E, Raclaw KA, Regan KM, et al. (2010) Differential regulation of steroid nuclear receptor coregulator expression between normal and neoplastic prostate epithelial cells. Prostate 70: 959-970.
16. Wang Q, Carroll JS, Brown M, (2005) Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell 19: 631-642.
17. Urbanucci A, Waltering KK, Suikki HE, Helenius MA, Visakorpi T, (2008) Androgen regulation of the androgen receptor coregulators. BMC Cancer 8: 219.
18. Powers CA, Mathur M, Raaka BM, Ron D, Samuels HH, (1998) TLS (translocated-in-liposarcoma) is a high-affinity interactor for steroid, thyroid hormone, and retinoid receptors. Mol Endocrinol 12: 4-18.
19. Rossow KL, Janknecht R, (2001) The Ewing's sarcoma gene product functions as a transcriptional activator. Cancer Res 61: 2690-2695.
20. Uranishi H, Tetsuka T, Yamashita M, Asamitsu K, Shimizu M, et al. (2001) Involvement of the pro-oncoprotein TLS (translocated in liposarcoma) in nuclear factor-kappa B p65-mediated transcription as a coactivator. J Biol Chem 276: 13395-13401.
21. Brooke GN, Culley RL, Dart DA, Mann DJ, Gaughan L, et al. FUS/TLS Is a Novel Mediator of Androgen-Dependent Cell-Cycle Progression and Prostate Cancer Growth. Cancer Res.
22. Kuroda M, Sok J, Webb L, Baechtold H, Urano F, et al. (2000) Male sterility and enhanced radiation sensitivity in TLS(-/-) mice. Embo J 19: 453-462.
23. Schauwaers K, De Gendt K, Saunders PT, Atanassova N, Haelens A, et al. (2007) Loss of androgen receptor binding to selective androgen response elements causes a reproductive phenotype in a knockin mouse model. Proc Natl Acad Sci U S A 104: 4961-4966.
24. De Gendt K, Swinnen JV, Saunders PT, Schoonjans L, Dewerchin M, et al. (2004) A Sertoli cell-selective knockout of the androgen receptor causes spermatogenic arrest in meiosis. Proc Natl Acad Sci U S A 101: 1327-1332.
25. Brinkmann AO, Klaasen P, Kuiper GG, van der Korput JA, Bolt J, et al. (1989) Structure and function of the androgen receptor. Urol Res 17: 87-93.
26. Snoek R, Rennie PS, Kasper S, Matusik RJ, Bruchovsky N, (1996) Induction of cell-free, in vitro transcription by recombinant androgen receptor peptides. J Steroid Biochem Mol Biol 59: 243-250.
27. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17: 535-546.
28. Romanuik TL, Wang G, Holt RA, Jones SJ, Marra MA, et al. (2009) Identification of novel androgen-responsive genes by sequencing of LongSAGE libraries. BMC Genomics 10: 476.
29. Wang G, Wang J, Sadar MD, (2008) Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. Cancer Res 68: 9918-9927.